Daniel Cadarette

Daniel Cadarette

Auto-generated profile, based on publicly available information

Daniel Cadarette

Harvard T.H. Chan School of Public Health, Boston, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2022 in eClinicalMedicine
Verified
Journal Article
Open access
KMKate Miller
Kate Miller
JCJonathan R. Carapetis
Jonathan R. Carapetis
CBChris A. Van Beneden
Chris A. Van Beneden
DCDaniel Cadarette
Daniel Cadarette
JDJessica N. Daw
Jessica N. Daw
JCJeffrey W. Cannon
Jeffrey W. Cannon
Contemporary data for the global burden of sore throat and group A Streptococcus (Strep A) pharyngitis are required to understand the frequency of disease and develop value propositions for Strep A vaccines. We used Clarivate Analytics’ Web of Science platform to search WoS core collection, PubMed, Medline, data citation index, KCI-Korean Journal Database, Russian Science Citation Index, and the SciELO Citation Index for articles published between Jan 1, 2000, and Feb 15, 2021, from any country and in any language. The risk of bias was assessed using the JBI critical appraisal checklist. We used random-effects meta-analyses to pool sore throat and Strep A sore throat incidence rates from community-based studies. Our study was registered with PROSPERO (CRD42020181103). Of 5,529 articles identified by the search strategy, 26 studies met the inclusion criteria, but only two included data to determine incidence among adults. The pooled incidence rate, calculated for children only, was 82.2 episodes per 100 child-years (95% CI 25.2–286.3, I2 = 100%) for sore throat (7 studies; 7,964 person years) and 22.1 episodes per 100 child-years (95% CI 14.7–33.1, I2 = 98%) for Strep A sore throat (9 studies; 15,696 person years). The pooled cumulative incidence rate of sore throat from five studies was 31.9 per 100 children. There was significant methodological and statistical heterogeneity among studies, and five of 26 studies had a risk of bias score less than five (range: nine [maximum score] to one). Strep A sore throat has a considerable global burden. However, methodologically standardised studies are required to quantify that burden, analyse differences in rates between populations, and evaluate the likely impact of future Strep A vaccines. This study was funded by Wellcome Trust 215,490/Z/19/Z.

10 June 2023 in npj Vaccines
Verified
Journal Article
Open access
PDF file
FGFiona Giannini
Fiona Giannini
JCJeffrey W. Cannon
Jeffrey W. Cannon
DCDaniel Cadarette
Daniel Cadarette
DBDavid E. Bloom
David E. Bloom
HMHannah C. Moore
Hannah C. Moore
KAKaja Abbas
Kaja Abbas
The World Health Organization published the preferred product characteristics for a Group AStreptococcus(Strep A) vaccine in 2018. Based on these parameters for the age of vaccination, vaccine efficacy, duration of protection from vaccine-derived immunity, and vaccination coverage, we developed a static cohort model to estimate the projected health impact of Strep A vaccination at the global, regional, and national levels and by country-income category. We used the model to analyse six strategic scenarios. Based on Strep A vaccine introduction between 2022 and 2034 for the primary scenario, we estimated vaccination at birth for 30 vaccinated cohorts could avert 2.5 billion episodes of pharyngitis, 354 million episodes of impetigo, 1.4 million episodes of invasive disease, 24 million episodes of cellulitis, and 6 million cases of rheumatic heart disease globally. Vaccination impact in terms of burden averted per fully vaccinated individual is highest in North America for cellulitis and in Sub-Saharan Africa for rheumatic heart disease.

30 October 2023 in npj Vaccines
Verified
Journal Article
Open access
PDF file
DCDaniel Cadarette
Daniel Cadarette
MFMaddalena Ferranna
Maddalena Ferranna
JCJeffrey W. Cannon
Jeffrey W. Cannon
KAKaja Abbas
Kaja Abbas
FGFiona Giannini
Fiona Giannini
DBDavid E. Bloom
David E. Bloom
Recent research has documented a wide range of health, economic, and social benefits conferred by vaccination, beyond the direct reductions in morbidity, mortality, and future healthcare costs traditionally captured in economic evaluations. In this paper, we describe the societal benefits that would likely stem from widespread administration of safe and effective vaccines against Streptococcus pyogenes (Strep A), which was estimated to be the fifth-leading cause of infectious disease deaths globally prior to the COVID-19 pandemic. We then estimate the global societal gains from prospective Strep A vaccination through a value-per-statistical-life approach. Estimated aggregate lifetime benefits for 30 global birth cohorts range from $1.7 to $5.1 trillion, depending on the age at which vaccination is administered and other factors. These results suggest that the benefits of Strep A vaccination would be large and justify substantial investment in the vaccines’ development, manufacture, and delivery.

3 August 2022 in medRxiv
Verified
Preprint
Open access
PDF file
FGFiona Giannini
Fiona Giannini
JCJeffrey W. Cannon
Jeffrey W. Cannon
DCDaniel Cadarette
Daniel Cadarette
DBDavid E. Bloom
David E. Bloom
HMHannah Moore
Hannah Moore
KAKaja Abbas
Kaja Abbas
The World Health Organization published the preferred product characteristics for a Group A Streptococcus (Strep A) vaccine in 2018. Based on these parameters for the age of vaccination, vaccine efficacy, duration of protection from vaccine-derived immunity, and vaccination coverage, we developed a static cohort model to estimate the projected health impact of Strep A vaccination at the global, regional, and national levels and by country-income category. We used the model to analyse six strategic scenarios. Based on Strep A vaccine introduction between 2022 and 2034 for the primary scenario, we estimated vaccination at birth for 30 vaccinated cohorts could avert 2.5 billion episodes of pharyngitis, 345 million episodes of impetigo, 1.3 million episodes of invasive disease, 24 million episodes of cellulitis, and 6 million cases of rheumatic heart disease globally. Vaccination impact in terms of burden averted per fully vaccinated individual is highest in North America for cellulitis and in Sub-Saharan Africa for rheumatic heart disease.

15 July 2023 in npj Vaccines
Verified
Journal Article
Open access
PDF file
FGFiona Giannini
Fiona Giannini
JCJeffrey W. Cannon
Jeffrey W. Cannon
DCDaniel Cadarette
Daniel Cadarette
DBDavid E. Bloom
David E. Bloom
HMHannah C. Moore
Hannah C. Moore
KAKaja Abbas
Kaja Abbas